Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec 23;9(1):2.
doi: 10.3390/diseases9010002.

Outcomes of Kidney Transplantation in Fabry Disease: A Meta-Analysis

Maria L Gonzalez Suarez  1   2 , Charat Thongprayoon  1 , Panupong Hansrivijit  3 , Juan Medaura  2 , Pradeep Vaitla  2 , Michael A Mao  4 , Tarun Bathini  5 , Boonphiphop Boonpheng  6 , Swetha R Kanduri  7 , Karthik Kovvuru  7 , Arpita Basu  8 , Wisit Cheungpasitporn  1
Affiliations

Outcomes of Kidney Transplantation in Fabry Disease: A Meta-Analysis

Maria L Gonzalez Suarez et al. Diseases. .

Abstract

Background: Fabry disease (FD) is a rare X-linked lysosomal storage disorder with progressive systemic deposition of globotriaosylceramide, leading to life-threatening cardiac, central nervous system, and kidney disease. Current therapy involves symptomatic medical management, enzyme replacement therapy (ERT), dialysis, kidney transplantation, and, more recently, gene therapy. The aim of this systematic review was to assess outcomes of kidney transplantation among patients with FD.

Methods: A comprehensive literature review was conducted utilizing MEDLINE, EMBASE, and Cochrane Database, from inception through to 28 February 2020, to identify studies that evaluate outcomes of kidney transplantation including patient and allograft survival among kidney transplant patients with FD. Effect estimates from each study were extracted and combined using the random-effects generic inverse variance method of DerSimonian and Laird.

Results: In total, 11 studies, including 424 kidney transplant recipients with FD, were enrolled. The post-transplant median follow-up time ranged from 3 to 11.5 years. Overall, the pooled estimated rates of all-cause graft failure, graft failure before death, and allograft rejection were 32.5% (95%CI: 23.9%-42.5%), 14.5% (95%CI: 8.4%-23.7%), and 20.2% (95%CI: 15.4%-25.9%), respectively. In the sensitivity analysis, limited only to the recent studies (year 2001 or newer when ERT became available), the pooled estimated rates of all-cause graft failure, graft failure before death, and allograft rejection were 28.1% (95%CI: 20.5%-37.3%), 11.7% (95%CI: 8.4%-16.0%), and 20.2% (95%CI: 15.5%-26.0%), respectively. The pooled estimated rate of biopsy proven FD recurrence was 11.1% (95%CI: 3.6%-29.4%), respectively. There are no significant differences in the risks of all-cause graft failure (p = 0.10) or mortality (0.48) among recipients with vs. without FD.

Conclusions: Despite possible FD recurrence after transplantation of 11.1%, allograft and patient survival are comparable among kidney transplant recipients with vs. without FD.

Keywords: Fabry disease; kidney transplant; kidney transplantation; meta-analysis; systematic review.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1
Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) flow diagram for study selection.
Figure 2
Figure 2
Rate of all-cause graft failure among kidney transplant patients with FD.
Figure 3
Figure 3
Risk of all-cause graft failure among kidney transplant patients with FD.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Germain D.P. Fabry disease. Orphanet J. Rare Dis. 2010;5:30. doi: 10.1186/1750-1172-5-30. - DOI - PMC - PubMed
    1. Germain D.P., Oliveira J.P., Bichet D.G., Yoo H.W., Hopkin R.J., Lemay R., Politei J., Wanner C., Wilcox W.R., Warnock D.G. Use of a rare disease registry for establishing phenotypic classification of previously unassigned GLA variants: A consensus classification system by a multispecialty Fabry disease genotype-phenotype workgroup. J. Med. Genet. 2020;57:542–551. doi: 10.1136/jmedgenet-2019-106467. - DOI - PMC - PubMed
    1. Ashley G.A., Shabbeer J., Yasuda M., Eng C.M., Desnick R.J. Fabry disease: Twenty novel alpha-galactosidase A mutations causing the classical phenotype. J. Hum. Genet. 2001;46:192–196. doi: 10.1007/s100380170088. - DOI - PubMed
    1. Ashton-Prolla P., Tong B., Shabbeer J., Astrin K.H., Eng C.M., Desnick R.J. Fabry disease: Twenty-two novel mutations in the alpha-galactosidase A gene and genotype/phenotype correlations in severely and mildly affected hemizygotes and heterozygotes. J. Investig. Med. 2000;48:227–235. - PubMed
    1. Davies J.P., Eng C.M., Hill J.A., Malcolm S., MacDermot K., Winchester B., Desnick R.J. Fabry disease: Fourteen alpha-galactosidase A mutations in unrelated families from the United Kingdom and other European countries. Eur. J. Hum. Genet. 1996;4:219–224. doi: 10.1159/000472202. - DOI - PubMed

LinkOut - more resources